Company / Accounts Receivable
Organon & Co. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.3B
FY2025
5-year range
$1.3B / $1.7B
FY2021-FY2025
Trend
-2.0%
vs FY2024
Sector context
#15 of 115
Health Care
What the data says
Organon & Co.'s accounts receivable of $1.3B is higher than 87% of companies in the Health Care sector (FY2025). Declined from $1.7B to $1.3B over the past 2 years.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Declined from $1.7B to $1.3B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -3.4%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 115This company $1.3B Sector average $1.1B
▼
+19.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, accounts receivable decreased 2.0% year-over-year.
- Ranks #15 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -2.0% |
| FY2024 | $1.4B | -22.1% |
| FY2023 | $1.7B | +18.2% |
| FY2022 | $1.5B | +6.7% |
| FY2021 | $1.4B | +33.1% |
| FY2020 | $1.0B | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026